iData Insights

Cancer Pain - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 02, 2016 15:33 IST

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179107/cancer-pain-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179107/cancer-pain-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cancer Pain Overview 8

Therapeutics Development 9

Pipeline Products for Cancer Pain - Overview 9

Pipeline Products for Cancer Pain - Comparative Analysis 10

Cancer Pain - Therapeutics under Development by Companies 11

Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13

Cancer Pain - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Cancer Pain - Products under Development by Companies 18

Cancer Pain - Products under Investigation by Universities/Institutes 20

Cancer Pain - Companies Involved in Therapeutics Development 21

Amgen Inc. 21

Amorsa Therapeutics Inc. 22

AngioChem Inc. 23

Aphios Corporation 24

AstraZeneca Plc 25

BCN Peptides, S.A. 26

Benitec Biopharma Limited 27

BioDelivery Sciences International, Inc. 28

ChironWells GmbH 29

Daiichi Sankyo Company, Limited 30

Fujimoto Pharmaceutical Corporation 31

Grunenthal GmbH 32

GW Pharmaceuticals Plc 33

Hisamitsu Pharmaceutical Co., Inc. 34

Immupharma Plc 35

IntelGenx Corp. 36

Kolon Life Science, Inc. 37

Nektar Therapeutics 38

Neurocentrx Pharma Ltd. 39

Orion Oyj 40

Pain Therapeutics, Inc. 41

Pfizer Inc. 42

Pharmaleads 43

PsychoGenics, Inc. 44

Recordati S.p.A. 45

Ribomic Inc. 46

Virobay Inc. 47

WEX Pharmaceuticals Inc. 48

Winston Pharmaceuticals, Inc. 49

Zynerba Pharmaceuticals, Inc. 50

Cancer Pain - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

AMS-410 ER12 - Drug Profile 61

ANG-2002 - Drug Profile 62

BBI-11008 - Drug Profile 63

buprenorphine hydrochloride - Drug Profile 64

calpastatin - Drug Profile 65

cebranopadol - Drug Profile 66

crotalphine - Drug Profile 68

DD-04107 - Drug Profile 69

dexmedetomidine hydrochloride - Drug Profile 70

dronabinol - Drug Profile 72

dronabinol - Drug Profile 73

Drug for Cancer Neuropathic Pain - Drug Profile 74

fentanyl - Drug Profile 75

fentanyl citrate - Drug Profile 76

fentanyl citrate - Drug Profile 77

fulranumab - Drug Profile 78

HP-3150 - Drug Profile 81

HS-198 - Drug Profile 82

hydromorphone hydrochloride - Drug Profile 83

IPP-102199 - Drug Profile 84

ketamine hydrochloride ER - Drug Profile 85

KLS-2020 - Drug Profile 86

methadone hydrochloride - Drug Profile 87

nabiximols - Drug Profile 88

Nervarna - Drug Profile 91

NKTR-192 - Drug Profile 93

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 94

PL-265 - Drug Profile 95

Q-201 - Drug Profile 96

QX-314 - Drug Profile 97

RBM-004 - Drug Profile 98

RBM-007 - Drug Profile 99

saracatinib difumarate - Drug Profile 100

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 102

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 103

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 104

tanezumab - Drug Profile 105

Tetrodotoxin - Drug Profile 108

VBY-825 - Drug Profile 110

ZJ-43 - Drug Profile 111

zucapsaicin - Drug Profile 112

ZYN-001 - Drug Profile 114

Cancer Pain - Recent Pipeline Updates 116

Cancer Pain - Dormant Projects 128

Cancer Pain - Discontinued Products 130

Cancer Pain - Product Development Milestones 131

Featured News & Press Releases 131

Appendix 137

Methodology 137

Coverage 137

Secondary Research 137

Primary Research 137

Expert Panel Validation 137

Contact Us 137

Disclaimer 138" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cancer Pain Overview 8

Therapeutics Development 9

Pipeline Products for Cancer Pain - Overview 9

Pipeline Products for Cancer Pain - Comparative Analysis 10

Cancer Pain - Therapeutics under Development by Companies 11

Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13

Cancer Pain - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Cancer Pain - Products under Development by Companies 18

Cancer Pain - Products under Investigation by Universities/Institutes 20

Cancer Pain - Companies Involved in Therapeutics Development 21

Amgen Inc. 21

Amorsa Therapeutics Inc. 22

AngioChem Inc. 23

Aphios Corporation 24

AstraZeneca Plc 25

BCN Peptides, S.A. 26

Benitec Biopharma Limited 27

BioDelivery Sciences International, Inc. 28

ChironWells GmbH 29

Daiichi Sankyo Company, Limited 30

Fujimoto Pharmaceutical Corporation 31

Grunenthal GmbH 32

GW Pharmaceuticals Plc 33

Hisamitsu Pharmaceutical Co., Inc. 34

Immupharma Plc 35

IntelGenx Corp. 36

Kolon Life Science, Inc. 37

Nektar Therapeutics 38

Neurocentrx Pharma Ltd. 39

Orion Oyj 40

Pain Therapeutics, Inc. 41

Pfizer Inc. 42

Pharmaleads 43

PsychoGenics, Inc. 44

Recordati S.p.A. 45

Ribomic Inc. 46

Virobay Inc. 47

WEX Pharmaceuticals Inc. 48

Winston Pharmaceuticals, Inc. 49

Zynerba Pharmaceuticals, Inc. 50

Cancer Pain - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

AMS-410 ER12 - Drug Profile 61

ANG-2002 - Drug Profile 62

BBI-11008 - Drug Profile 63

buprenorphine hydrochloride - Drug Profile 64

calpastatin - Drug Profile 65

cebranopadol - Drug Profile 66

crotalphine - Drug Profile 68

DD-04107 - Drug Profile 69

dexmedetomidine hydrochloride - Drug Profile 70

dronabinol - Drug Profile 72

dronabinol - Drug Profile 73

Drug for Cancer Neuropathic Pain - Drug Profile 74

fentanyl - Drug Profile 75

fentanyl citrate - Drug Profile 76

fentanyl citrate - Drug Profile 77

fulranumab - Drug Profile 78

HP-3150 - Drug Profile 81

HS-198 - Drug Profile 82

hydromorphone hydrochloride - Drug Profile 83

IPP-102199 - Drug Profile 84

ketamine hydrochloride ER - Drug Profile 85

KLS-2020 - Drug Profile 86

methadone hydrochloride - Drug Profile 87

nabiximols - Drug Profile 88

Nervarna - Drug Profile 91

NKTR-192 - Drug Profile 93

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 94

PL-265 - Drug Profile 95

Q-201 - Drug Profile 96

QX-314 - Drug Profile 97

RBM-004 - Drug Profile 98

RBM-007 - Drug Profile 99

saracatinib difumarate - Drug Profile 100

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 102

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 103

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 104

tanezumab - Drug Profile 105

Tetrodotoxin - Drug Profile 108

VBY-825 - Drug Profile 110

ZJ-43 - Drug Profile 111

zucapsaicin - Drug Profile 112

ZYN-001 - Drug Profile 114

Cancer Pain - Recent Pipeline Updates 116

Cancer Pain - Dormant Projects 128

Cancer Pain - Discontinued Products 130

Cancer Pain - Product Development Milestones 131

Featured News & Press Releases 131

Appendix 137

Methodology 137

Coverage 137

Secondary Research 137

Primary Research 137

Expert Panel Validation 137

Contact Us 137

Disclaimer 138

Read More http://www.idatainsights.com/reports-landing-page.php?id=179107/cancer-pain-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.